Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy

2020 ◽  
pp. 1-10
Author(s):  
Chiara Molinelli ◽  
Francesca Parisi ◽  
Maria Grazia Razeti ◽  
Luca Arecco ◽  
Maurizio Cosso ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Adjuvant Treatment ◽  
Trastuzumab Emtansine ◽  
Her2 Positive ◽  
Safety And Efficacy

scholarly journals FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer

2020 ◽  
Vol 26 (16) ◽  
pp. 4180-4185 ◽  
Author(s):  
Suparna Wedam ◽  
Lola Fashoyin-Aje ◽  
Xin Gao ◽  
Erik Bloomquist ◽  
Shenghui Tang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Adjuvant Treatment ◽  
Trastuzumab Emtansine ◽  
Her2 Positive ◽  
Fda Approval

scholarly journals The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer

ESMO Open ◽  
2021 ◽  
Vol 6 (2) ◽  
pp. 100074
Author(s):  
J. Delgado ◽  
C. Vleminckx ◽  
S. Sarac ◽  
A. Sosa ◽  
J. Bergh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Adjuvant Treatment ◽  
Adult Patients ◽  
Trastuzumab Emtansine ◽  
Her2 Positive

Misconception on the duration of ado-trastuzumab emtansine treatment for HER2-positive early breast cancer

2022 ◽  
Author(s):  
Clement Chung
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Trastuzumab Emtansine ◽  
Her2 Positive ◽  
Final Version ◽  
Final Article

Disclaimer In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.

Trastuzumab emtansine: a game changer in HER2-positive early breast cancer

2020 ◽  
Vol 16 (32) ◽  
pp. 2595-2609
Author(s):  
Max S Mano
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Pathological Complete Response ◽  
Growth Factor Receptor ◽  
Complete Response ◽  
Trastuzumab Emtansine ◽  
Her2 Positive ◽  
Adjuvant Trastuzumab ◽  
Epidermal Growth ◽  
Game Changer

Trastuzumab emtansine (T-DM1), given postoperatively for 14 cycles to patients with human epidermal growth factor receptor 2-positive (HER2-positive) early breast cancer (EBC) who failed to achieve a pathological complete response after standard chemotherapy and HER2 blockade, represents probably the greatest progress in the management of this aggressive form of breast cancer since the adjuvant trastuzumab pivotal trials. This article addresses the rationale behind the conception of the KATHERINE trial, T-DM1’s structure and pharmacokinetics data, clinical efficacy data of the KATHERINE trial and of other EBC trials with T-DM1, safety aspects, implications of the KATHERINE trial results to clinical practice and future perspectives in the management of HER2-positive EBC.

Sign in / Sign up

Export Citation Format

Share Document